Another strategist chops his S&P 500 target — but for a different reason than the Goldman Sachs reduction
The reduction by Ed Yardeni, president and chief investment strategist of Yardeni Research, is notable for a few reasons, one ...
Goldman's Oppenheimer warns U.S. stock market may continue to underperform
Goldman Sachs analysts are cautioning that “confidence in the US growth story is moderating” and the U.S. stock market may continue to lag behind other global markets.
The Goldman Sachs Group Cuts EverCommerce (NASDAQ:EVCM) Price Target to $8.00
EverCommerce (NASDAQ:EVCM – Get Free Report) had its price objective decreased by research analysts at The Goldman Sachs ...
An S&P correction exceeding 10% will inflict pain on global stocks, Goldman says
Goldman looked at periods of S&P 500 ( SP500) corrections above 10% since 1990. Its broad observation was that, in absolute ...
Arvinas (NASDAQ:ARVN) Lowered to Neutral Rating by The Goldman Sachs Group
Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by The Goldman Sachs Group from a “buy” rating to a “neutral” rating ...
SCHD ETF analysis as Citi, Goldman Sachs, HSBC slash S&P 500 forecast
What next for the SCHD ETF now that analysts at Citigroup, Goldman Sachs, and HSBC have slashed their S&P 500 forecast?
Morningstar3d
Another strategist chops his S&P 500 target - but for a different reason than the Goldman Sachs reduction
(Oppenheimer as of pixel time has the top ... But also what's unique is how he compared and contrasted his view with that of Goldman Sachs, which this week lowered its S&P 500 target down to ...
Tarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50
The deal size was increased to $125M in common stock from $100M in common stock. Goldman Sachs, BofA, Barclays and Oppenheimer acted as joint ...